Novartis Manipulated Data in FDA Biologics License Application
On Aug. 6, 2019, the U.S. Food and Drug Administration (FDA) issued a statement saying that Swiss pharmaceutical company Novartis AG submitted a biologics license application (BLA) for the spinal muscular atrophy (SMA) gene therapy Zolgensma (onasemnogene abeparvovec-xioi) with manipulated data and failed to inform regulators until June 28, 2019—more than a month after the […]
Google Joins the Pharmaceutical Industry
Story Highlights Google, the world’s most widely used internet search engine, restructured itself to give semi-independence to its many subsidiary organizations under a new umbrella entity called Alphabet. Two of the divisions are focused on the business of medicine and operate in partnership with some of the world’s most powerful pharmaceutical companies that develop and […]